Abatacept for Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT.Participants will:* Partake in exams, tests, and procedures as part of usual cancer care.* Partake in conditioning, which is the treatment that is given before a transplant.* Have a cord blood transplant.* Partake in radiation following the transplant.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, it mentions that concurrent therapy for certain conditions like testicular leukemia and CNS lymphoma is allowed, so you might be able to continue some treatments. It's best to discuss your specific medications with the trial team.
Is abatacept safe for humans?
Abatacept, also known as Orencia, has been studied for safety in patients with rheumatoid arthritis. In these studies, the overall safety profile was similar to placebo, with low rates of serious infections and malignancies. However, there was a case of squamous-cell carcinoma possibly linked to abatacept, indicating the need for more research on long-term risks.12345
How does the drug Abatacept differ from other leukemia treatments?
Abatacept is unique because it is primarily used to treat autoimmune conditions like rheumatoid arthritis by modulating the immune system, whereas most leukemia treatments focus on directly targeting cancer cells or their growth pathways. This approach may offer a novel way to manage leukemia by potentially altering the immune environment around the cancer.678910
Who Is on the Research Team?
Leland Metheny, MD
Principal Investigator
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with certain blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. It's also open to those with specific genetic conditions such as Klinefelter or Triple X Syndrome. Participants must be suitable for a cord blood transplant and able to undergo pre-transplant conditioning treatments including radiation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Conditioning
Participants undergo conditioning treatment before the transplant, including Cyclophosphamide, Fludarabine, Thiotepa, and Total Body Irradiation
Transplant
Participants receive a double umbilical cord blood transplant
Radiation
Participants undergo radiation following the transplant
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments for aGVHD and other outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Abatacept
Find a Clinic Near You
Who Is Running the Clinical Trial?
Leland Metheny
Lead Sponsor